SecBot SecBot
6-K ·Filed Nov 2, 2026

KMDA

KAMADA LTD
NEUTRAL
Impact 2/10
Horizondays Processed14d 17h ago SEC0001213900-26-114649
Notable filing: 6-K
Actionable Insight • Neutral

Monitor the November 9 earnings release for Q3 2026 revenue and EPS against consensus of $157.4M and $0.13 per ADS, respectively. The prior quarter (Q2 2026) showed a beat versus consensus.

DirectionNeutral
Confidencehigh
Horizondays

Drugs in focus

KMDA drug pipeline →

CYTOGAM

● Neutral Named in this 6-K
Impact
Phase
Approved
Time to market
Already FDA-approved and commercially marketed
Next catalyst
None dated

What to watchCYTOGAM contributes ~12-13% of Kamada's total revenue (~$22.5M in 2024) and is growing 31% YoY, but is not a binary catalyst for the stock. Watch Q2 2026 earnings (~Aug 12, 2026) for CYTOGAM sales trajectory and any updates on the SHIELD study. The stock's primary drivers are Glassia (alpha-1 antitrypsin) and KEDRAB (rabies IG), which represent larger revenue streams.

How the stock moved after the report

NEUTRAL VIEWSTOCK ABOVE ENTRY AT T+5
Entry
$7.36
T+0 close · Nov 2, 2026 · via day close
Latest settled
+4.76%
T+5 · $7.71 · next T+20 in 14d
Vs SPY
+4.68%
α at T+5
Latest observation
+10.81%
T+9 · FF3 residual α
  1. T+0 · Nov 2 $7.36entry
  2. T+1 · 14d ago −1.49%α −1.79% · $7.25
  3. T+5 · 8d ago +4.76%α +4.68% · $7.71
  4. T+10 · todayOpen
  5. T+20 · in 14d Pending
  6. T+60 · in 2mo Pending
Loading chart...

How similar events traded

How similar events traded

See how far stocks moved after events like this one.

Subscribe for Full Access

Executive Summary

Kamada Ltd. filed a Form 6-K announcing that it will release Q3 and nine-month 2026 financial results on November 9, 2026, before market open, with a conference call at 8:30am ET. This is a routine results-date notice with no financial data, guidance, or material events.

Key Facts

  • Kamada will release Q3 and nine-month 2026 results on November 9, 2026, prior to U.S. market open.
  • A conference call is scheduled for November 9, 2026 at 8:30am ET.
  • No financial results, guidance, or material operational updates were disclosed in this filing.
  • The filing is a routine results-date announcement under Form 6-K.

Financial Impact

No financial data disclosed in this filing.

Risk Factors

  • No financial data or guidance in this filing; all material information will be released on November 9.

Market Snapshot

Exchange
Nasdaq
Sector
Pharmaceutical Preparations
Analyst Consensus
89% bullish (9 analysts)

Investment Themes

Documents Analyzed

This report is based on 6 SEC documents filed with EDGAR.

DocumentAccession Number
6-K Filing (Primary)0001213900-26-114649
Document: ea031047301ex99-1.htm0001213900-26-114649
Document: 0001213900-26-114649-index-headers.html0001213900-26-114649
Document: 0001213900-26-114649-index.html0001213900-26-114649
Document: 0001213900-26-114649.txt0001213900-26-114649
Earnings Context (Synthetic; results releases only)0001213900-26-114649

Track record

25 reports on KMDA

Performance horizon

8 of 11 bullish or bearish reports moved the stock their way by T+5. Best: +16.13% at T+20 after the Aug 12, 2026 report. 10 of 11 went positive at some point.

Filters
  1. Nov 9, 20267d ago 6-K Bullish 6/10 No price data
  2. Nov 9, 20267d ago Press Release Bullish 6/10 Entry $7.71 to $8.11 Now $8.11 +5.19% ▲ +5.19% +6.88% vs SPY
  3. Nov 2, 202614d ago 6-K Neutral 2/10 Viewing Entry $7.36 to $7.71 Now $8.11 +10.19% ▲ +4.76% +4.68% vs SPY
  4. Oct 6, 20265w ago 6-K Neutral 4/10 Entry $8.11 to $7.69 Now $8.11 −0.00% ▼ −5.18% −5.04% vs SPY
  5. Oct 6, 20265w ago Press Release Bullish 6/10 Entry $8.11 to $7.69 Now $8.11 −0.00% ▼ −5.18% −5.04% vs SPY
  6. Oct 5, 20266w ago 6-K Neutral 2/10 Entry $8.11 to $7.69 Now $8.11 −0.00% ▼ −5.18% −5.04% vs SPY
  7. Sep 17, 20268w ago 6-K Bullish 6/10 Entry $8.67 to $8.83 Now $8.11 −6.46% ▲ +1.85% +1.24% vs SPY
  8. Sep 16, 20268w ago EFFECT Neutral 3/10 Entry $8.19 to $8.77 Now $8.11 −0.98% ▲ +7.08% +4.52% vs SPY
  9. Sep 10, 20269w ago 6-K Neutral 2/10 Entry $7.99 to $8.67 Now $8.11 +1.50% ▲ +8.51% +9.01% vs SPY
  10. Sep 3, 202610w ago Press Release Neutral 2/10 Entry $8.54 to $8.31 Now $8.11 −5.04% ▼ −2.69% −1.48% vs SPY
Showing 10 of 25

US Market Status

Market Closed · Opens in 9h 25m

Subscribe to SecBot

Get Real-Time SEC Filing Intelligence

Comprehensive SEC filing analysis delivered the moment filings hit EDGAR. Sentiment scoring, impact analysis, and actionable insights for every material event.

Create a free account Live analysis, Telegram alerts, watchlists and the MCP server for subscribers
Report published Nov 2, 2026